Grail’s stock was the Nasdaq’s biggest loser Friday, after a key trial of its Galleri early-detection cancer test failed to meet its primary endpoint.
This once-hot cancer-detection company’s stock got cut in half after a failed trial
Related Posts
Popular News
Latest News
Tokenized Real Estate Projects Advance in Dubai and the Maldives
Entities in Dubai and the archipelagic nation of the Maldives are moving forward with tokenized real estate development projects worth...
Don’t expect lower prices now that the Supreme Court ruled against Trump’s tariffs
The Supreme Court’s decision to strike down many of President Donald Trump’s tariffs is a massive blow to the president’s...
Meta Is Taking VR Out of ‘Horizon Worlds’
Meta just announced a seismic change to its 3D social platform Horizon Worlds. The company is removing Meta Quest users...
SEC slashes stablecoin haircut from 100% to just 2%
SEC cuts payment stablecoin haircuts to 2%, boosting on‑chain settlement economics for broker‑dealers. Summary New SEC FAQ says staff “would...
Welcome to Global Finances Daily, your go-to source for all things finance. Our mission is to provide our readers with valuable information and insights to help them achieve their financial goals and secure their financial future.